Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830397 | 0.88 | PNMT (0.57) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL8671794 | 0.87 | PNMT (0.55) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL1830400 | 0.87 | PNMT (0.55) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL135489 | 0.85 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL8473291 | 0.85 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL7699409 | 0.85 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL8473288 | 0.85 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL6502789 | 0.85 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL425742 | 0.85 | PNMT (0.58) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL29892750 | 0.85 | PNMT (0.58) | PNMTNPC1RAB9AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650827-A | Preparation method, intermediate compound and synthesis method for anthracycline derivatives | 戊言医药科技（上海）有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115651043-A | Preparation method of anthracycline derivative | 戊言医药科技（上海）有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-114853822-A | Oligonucleotide-disulfide and synthetic method thereof | 康龙化成(宁波)科技发展有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-108070009-B | Method for preparing DNA coding compound library and initial fragment compound and prepared DNA coding compound | 上海药明康德新药开发有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-107629016-B | Evans blue complex and preparation method and application thereof | 莎穆(上海)生物科技有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | claimed |
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | claimed |
| WO-2017068596-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-04-27 | — | — | WO | claimed |
| JP-2007509921-A | — | — | 2007-04-19 | — | — | JP | claimed |
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-02-22 | — | — | US | claimed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | claimed |
| WO-2003048116-A2 | ESTERS AND AMIDES AS PPAR-ALPHA AGONISTS ____________ | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-12 | — | — | WO | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1240157-A2 | SUBSTITUTED N-BENZYL-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES HAVING AN ANTI-TUMORAL EFFECT | Zentaris AG (DE) | 2002-09-18 | — | — | EP | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2001047913-A2 | SUBSTITUTED N-BENZYL-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES HAVING AN ANTI-TUMORAL EFFECT | ZENTARIS AG (DE) | 2001-07-05 | — | — | WO | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| WO-1999002532-A2 | PARTIALLY HYDROGENATED POLYCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998033776-A1 | COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | IL17A, HSD17B7, SULT1E1 | PNMT 2610/4885NPC1 4716/4885RAB9A 3840/4885 |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | PNMT 2710/4885NPC1 25/4885RAB9A 1079/4885 |
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, LIPC | PNMT 3018/4885NPC1 44/4885RAB9A 1734/4885 |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | SULT1E1, IL17A, TET1 | PNMT 2049/4885NPC1 4608/4885RAB9A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.